SCHEMBL22513

SCHEMBL22513

CCCCCCCCC(C)CC(=O)O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 10/20 0.64
ACE2 Q9BYF1 1/20 0.62
FFAR1 O14842 3/20 0.52
FFAR4 Q5NUL3 2/20 0.52
PPARD Q03181 6/20 0.50
MAPT P10636 1/20 0.50
LCK P06239 1/20 0.50
ZDHHC20 Q5W0Z9 1/20 0.50
ZDHHC2 Q9UIJ5 1/20 0.50
PPARG P37231 5/20 0.48
PPARA Q07869 5/20 0.48
HDAC11 Q96DB2 4/20 0.48
TSHR P16473 3/20 0.48
ALDH1A1 P00352 2/20 0.48
TLR2 O60603 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
FABP4 P15090 2/20 0.48
PTPN1 P18031 2/20 0.48
SLC22A6 Q4U2R8 1/20 0.48
SLC22A8 Q8TCC7 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8049901 1.00 GPR84 (0.64) GPR84ACE2FFAR1FFAR4PPARD
SCHEMBL1872991 1.00 GPR84 (0.64) GPR84ACE2FFAR1FFAR4PPARD
SCHEMBL22240 1.00 GPR84 (0.64) GPR84ACE2FFAR1FFAR4PPARD
SCHEMBL17772493 1.00 GPR84 (0.64) GPR84ACE2FFAR1FFAR4PPARD
SCHEMBL3305087 1.00 GPR84 (0.64) GPR84ACE2FFAR1FFAR4PPARD
SCHEMBL7823853 1.00 GPR84 (0.64) GPR84ACE2FFAR1FFAR4PPARD
SCHEMBL23930717 1.00 GPR84 (0.64) GPR84ACE2FFAR1FFAR4PPARD
SCHEMBL2343127 1.00 GPR84 (0.64) GPR84ACE2FFAR1FFAR4PPARD
SCHEMBL22612526 1.00 GPR84 (0.64) GPR84ACE2FFAR1FFAR4PPARD
SCHEMBL22612511 1.00 GPR84 (0.64) GPR84ACE2FFAR1FFAR4PPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250057798-A1 THERAPEUTIC USE OF COMPOUNDS UCL BUSINESS LTD (GB) 2025-02-20 US claimed
US-20230146709-A1 THERAPEUTIC USE OF COMPOUNDS UCL BUSINESS LTD (GB) 2023-05-11 US claimed
US-11246823-B2 Molecularly imprinted polymer of sol-gel type for selectively trapping odorous molecules L'OREAL (FR) 2022-02-15 US claimed
EP-2737901-B1 Therapeutic Use of Compounds UCL BUSINESS LTD (GB) 2021-03-03 EP claimed
US-20200268699-A1 THERAPEUTIC USE OF COMPOUNDS UCL BUSINESS LTD (GB) 2020-08-27 US claimed
US-20200197344-A1 THERAPEUTIC USE OF COMPOUNDS UCL BUSINESS LTD (GB) 2020-06-25 US claimed
EP-3636259-A1 THERAPEUTIC USE OF COMPOUNDS UCL BUSINESS LTD (GB) 2020-04-15 EP claimed
EP-2642990-B1 THERAPEUTIC USE OF COMPOUNDS UCL BUSINESS PLC (GB) 2019-09-18 EP claimed
US-10017790-B2 Whole-cell biotransformation of fatty acids to obtain fatty aldehydes shortened by one carbon atom SYMRISE AG (DE) 2018-07-10 US claimed
EP-2938654-B1 MOLECULARLY IMPRINTED POLYMER OF SOL-GEL TYPE FOR SELECTIVELY TRAPPING ODOROUS MOLECULES OREAL (FR) 2016-08-24 EP claimed
WO-2014102078-A1 MOLECULARLY IMPRINTED POLYMER OF SOL-GEL TYPE FOR SELECTIVELY TRAPPING ODOROUS MOLECULES L'OREAL (FR) 2014-07-03 WO claimed
WO-2014102077-A1 MOLECULARLY IMPRINTED POLYMER FOR SELECTIVELY TRAPPING ODOROUS MOLECULES L'OREAL (FR) 2014-07-03 WO claimed
EP-2737901-A1 Therapeutic Use of Compounds UCL Business PLC (GB) 2014-06-04 EP claimed
US-20130303616-A1 THERAPEUTIC USE OF COMPOUNDS UCL BUSINESS PLC (GB) 2013-11-14 US claimed
EP-2642990-A1 THERAPEUTIC USE OF COMPOUNDS UCL Business Plc. (GB) 2013-10-02 EP claimed
CN-103327973-A Therapeutic use of compounds UCL BUSINESS PLC 2013-09-25 CN claimed
EP-2609207-A1 WHOLE-CELL BIOTRANSFORMATION OF FATTY ACIDS TO OBTAIN FATTY ALDEHYDES SHORTENED BY ONE CARBON ATOM Symrise AG (DE) 2013-07-03 EP claimed
US-20130149756-A1 Whole-Cell Biotransformation Of Fatty Acids To Obtain Fatty Aldehydes Shortened By One Carbon Atom SYMRISE AG (DE) 2013-06-13 US claimed
WO-2012069790-A1 THERAPEUTIC USE OF COMPOUNDS ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) 2012-05-31 WO claimed
WO-2012025629-A1 WHOLE-CELL BIOTRANSFORMATION OF FATTY ACIDS TO OBTAIN FATTY ALDEHYDES SHORTENED BY ONE CARBON ATOM SYMRISE AG (DE) 2012-03-01 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230146709-A1 THERAPEUTIC USE OF COMPOUNDS SGMS1, CHRM1, CYP11B1 GPR84 839/4885ACE2 2018/4885FFAR1 85/4885
US-20200268699-A1 THERAPEUTIC USE OF COMPOUNDS DEGS1, CYP11B1, SGMS1 GPR84 1057/4885ACE2 2571/4885FFAR1 149/4885
US-20130303616-A1 THERAPEUTIC USE OF COMPOUNDS BACE1, CPT1A, BCL6 GPR84 849/4885ACE2 2880/4885FFAR1 194/4885
US-20250057798-A1 THERAPEUTIC USE OF COMPOUNDS CYP11B1, SGMS1, PTGER1 GPR84 630/4885ACE2 1765/4885FFAR1 66/4885
US-11246823-B2 Molecularly imprinted polymer of sol-gel type for selectively trapping odorous molecules TAS2R30, TAS1R1, TAS2R10 GPR84 471/4885ACE2 4321/4885FFAR1 2567/4885
US-20200197344-A1 THERAPEUTIC USE OF COMPOUNDS SGMS1, CHRM1, CYP11B1 GPR84 839/4885ACE2 2018/4885FFAR1 85/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.